Aurinia Pharmaceuticals Inc. (AUPH) Stocks Experience Steady decrease to Close at $8.84


Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) closed the day trading at $8.84 down -2.64% from the previous closing price of $9.08. In other words, the price has decreased by -$0.24 from its previous closing price. On the day, 1534831 shares were traded. AUPH stock price reached its highest trading level at $9.12 during the session, while it also had its lowest trading level at $8.83.

Do You Know The Best Place To Find Gains In Volatile Markets?

In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.

Click here for full details and to join for free


For a better understanding of AUPH, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.20 and its Current Ratio is at 6.70. In the meantime, Its Debt-to-Equity ratio is 0.24 whereas as Long-Term Debt/Eq ratio is at 0.20.

Upgrades & Downgrades

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 23 when Jayne David R.W. sold 8,733 shares for $11.26 per share. The transaction valued at 98,334 led to the insider holds 49,310 shares of the business.

MacKay-Dunn R. Hector sold 4,818 shares of AUPH for $54,251 on May 23. The Director now owns 24,225 shares after completing the transaction at $11.26 per share. On May 23, another insider, Leversage Jill, who serves as the Director of the company, sold 4,815 shares for $11.26 each. As a result, the insider received 54,217 and left with 18,528 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AUPH now has a Market Capitalization of 1.27B and an Enterprise Value of 1.02B. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.13 while its Price-to-Book (P/B) ratio in mrq is 3.21. Its current Enterprise Value per Revenue stands at 6.94 whereas that against EBITDA is -10.12.

Stock Price History:

Over the past 52 weeks, AUPH has reached a high of $12.43, while it has fallen to a 52-week low of $4.07. The 50-Day Moving Average of the stock is 10.08, while the 200-Day Moving Average is calculated to be 9.15.

Shares Statistics:

Over the past 3-months, AUPH traded about 2.14M shares per day on average, while over the past 10 days, AUPH traded about 1.72M shares per day. A total of 142.78M shares are outstanding, with a floating share count of 133.37M. Insiders hold about 0.10% of the company’s shares, while institutions hold 40.50% stake in the company. Shares short for AUPH as of Aug 30, 2023 were 13.96M with a Short Ratio of 13.96M, compared to 15.82M on Jul 30, 2023. Therefore, it implies a Short% of Shares Outstanding of 9.73% and a Short% of Float of 9.76%.

Earnings Estimates

Current recommendations for the stock of the company come from Aurinia Pharmaceuticals Inc analysts. The consensus estimate for the next quarter is $85.72, with high estimates of $1.20 and low estimates of $45.77.

Analysts are recommending an EPS of between $Healthcare and $Healthcare for the fiscal current year, implying an average EPS of $Technology. EPS for the following year is $Stocks, with Stocks analysts recommending between $Stocks and $Stocks.


Please enter your comment!
Please enter your name here